Biologics CDMO Services

ProBio is a global CDMO supporting biologics and advanced therapy development across the product lifecycle. With proven expertise in challenging molecules such as proteins and bispecific antibodies, we deliver high‑quality and end‑to‑end services from discovery to commercialization, supported by professional solutions and well‑controlled efficient processes.

Our Services & Solutions

End‑to‑end protein and antibody development, engineered to de‑risk complexity and accelerate your path to clinic and beyond.

Cell Line Development Solutions for Biomanufacturing

10 weeks from DNA to top 6 clones.

Antibody and Protein Drug DNA to IND Solutions – 4 Months to Tox Drug Substance

Antibody & Protein Drug DNA to IND Solutions

4 months from DNA to tox drug substance production completion.

Antibody & Protein Drug IND to BLA Solutions

BLA readiness in 14 months.

ProBio Biologics CDMO Services – End-to-End Protein and Antibody Development

Protein and Antibody Development Process

Proven Biologics Delivery,
Designed to De‑Risk Every Step

News

ProBio Accelerates Chimagen’s Global Market Expansion, Paving the Way for Innovative Antibody Therapy

ProBio is proud to support its partner Chengdu Chimagen Biosciences Co., Ltd (Chimagen), in a landmark strategic agreement with pharmaceutical leader GlaxoSmithKline (GSK).

Learn More

Brochure

Protein and Antibody Drug CDMO Service – Developing Complex Molecules Easily

From pre-clinical to late stage commercialization, ProBio offers solutions to de-risk every stage and drive productivity. You bring the idea, we bring the expertise to bring it to market.

Learn More

Video